|
US2021032293A1
|
|
KRAS-Specific Capture Agents, Compositions, and Methods of Making and Using
|
|
US2020323973A1
|
|
Epitope-targeted peptide immunostimulants
|
|
WO2020209988A2
|
|
Diverse marker panel for ptsd diagnosis and treatment
|
|
WO2020096984A1
|
|
Sepsis biomarker panels and methods of use
|
|
WO2019135952A1
|
|
Circulating biomarker signatures for lyme disease diagnosis and treatment
|
|
US2020395095A1
|
|
Method and system for generating and comparing genotypes
|
|
WO2017210102A1
|
|
Methods and system for generating and comparing reduced genome data sets
|
|
US2020013480A1
|
|
Methods for identifying treatment targets based on multiomics data
|
|
US2019084929A1
|
|
Crosslinkers for mass spectrometric identification and quantitation of peptides
|
|
EP3380195A1
|
|
Methods to identify antituberculosis compounds
|
|
US2017010229A1
|
|
Method to obtain unbiased identification of interaction of test compounds with the proteome
|
|
AU2015279660A1
|
|
Markers and therapeutic indicators for glioblastoma multiforme (GBM)
|
|
US2015253324A1
|
|
Point of care assays to detect the status of tuberculosis infection
|
|
AU2013203290A1
|
|
Nanoreporters and methods of manufacturing and use thereof
|
|
US2014073516A1
|
|
Markers and methods for detecting posttraumatic stress disorder (PTSD)
|
|
JP2011226970A
|
|
Automatic analysis of images using bright field microscope
|
|
AU2007284651A1
|
|
Organ-specific proteins and methods of their use
|
|
AU2006304605A1
|
|
Tissue-and serum-derived glycoproteins and methods of their use
|
